IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522373-10-00

Enrollment

253

Registered

2026-06-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis

Brief summary

Track the number of side effects that happen after starting the treatment, including serious side effects, side effects that cause someone to stop taking the medicine, and any deaths., Assess changes in lab test results, heart tests (ECG), and vital signs like blood pressure and heart rate over time and compare any changes to what they were on the first day of the study.

Interventions

DRUGLPA1 antagonist

DRUGBMS-986278

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Track the number of side effects that happen after starting the treatment, including serious side effects, side effects that cause someone to stop taking the medicine, and any deaths., Assess changes in lab test results, heart tests (ECG), and vital signs like blood pressure and heart rate over time and compare any changes to what they were on the first day of the study.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 19, 2026